Sarcoma
769
120
164
394
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
119 trials with published results (15%)
Research Maturity
394 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.7%
90 terminated out of 769 trials
81.4%
-5.1% vs benchmark
6%
45 trials in Phase 3/4
30%
119 of 394 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 394 completed trials
Clinical Trials (769)
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
IDOV-Immune for Advanced Solid Tumors
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
GRID Therapy for Extremity Soft Tissue Sarcoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
DESTINY-PANTUMOUR04
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)